SCHEMBL7070128

SCHEMBL7070128

C=C(C)COc1ccc2c(=O)c(C)c(-c3ccccc3)oc2c1C(=O)C=Cc1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KRAS P01116 3/20 0.42
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
LMNA P02545 4/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PLIN1 O60240 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
PLIN5 Q00G26 1/20 0.41
ABHD5 Q8WTS1 1/20 0.41
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 1/20 0.39
TNFRSF1A P19438 2/20 0.39
ABCB1 P08183 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7072240 0.91 ALOX5 (0.50) KRASPDE4APDE4BPDE4CPDE4D
SCHEMBL7072943 0.90 ALDH1A1 (0.41) LMNAMAPTSMN1; SMN2GAAHTT
SCHEMBL7072948 0.90 KRAS (0.43) KRASPDE4APDE4BPDE4CPDE4D
SCHEMBL7073634 0.88 NQO1 (0.45) LMNAMAPTSMN1; SMN2PLIN1GAA
SCHEMBL7192689 0.87 KRAS (0.42) KRASPDE4APDE4BPDE4CPDE4D
SCHEMBL6903339 0.82 MAPT (0.60) KRASLMNAMAPTSMN1; SMN2PLIN1
SCHEMBL7070586 0.82 KDM4E (0.49) PDE4ALMNAMAPTSMN1; SMN2GAA
SCHEMBL7073297 0.80 MAOB (0.43) PDE4ALMNAMAPTSMN1; SMN2GAA
SCHEMBL7070595 0.79 MAOB (0.40) PDE4ALMNAMAPTSMN1; SMN2GAA
SCHEMBL7069986 0.79 ABCB1 (0.46) LMNAMAPTKMT2AABCB1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1212315-B1 NOVEL CHALCONES INDENA SPA (IT) 2003-03-26 EP claimed
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth INDENA S.P.A. (IT) 2003-03-20 US claimed
EP-1212315-A1 NOVEL CHALCONES INDENA S.p.A. (IT) 2002-06-12 EP claimed
WO-2001017988-A1 NOVEL CHALCONES INDENA S.P.A. (IT) 2001-03-15 WO claimed
US-6620842-B2 Chalcones INDENA SPA (IT) 2003-09-16 US disclosed
EP-1212315-B1 NOVEL CHALCONES INDENA SPA (IT) 2003-03-26 EP disclosed
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth INDENA S.P.A. (IT) 2003-03-20 US disclosed
EP-1212315-A1 NOVEL CHALCONES INDENA S.p.A. (IT) 2002-06-12 EP disclosed
WO-2001017988-A1 NOVEL CHALCONES INDENA S.P.A. (IT) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth HDGF, MKI67, HPD KRAS 1768/4885PDE4A 1603/4885PDE4B 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.